drugset / Trial / NCT05625919

A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

NCT05625919

Phase 1/2 Unknown 54 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase Ⅰb/Ⅱ multi-center study of safety and efficacy of Sirolimus for Injection (Albumin-bound) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).

Timeline

Start
2022-11-08
Primary completion
2024-11
Completion
2024-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule Intravenous